PURPOSE: From the randomized study Southwest Oncology Group 8794 we evaluated the effect of seminal vesicle involvement on outcomes and whether those patients benefited from post-prostatectomy adjuvant radiation therapy. MATERIALS AND METHODS:Southwest Oncology Group study 8794 randomized high risk patients (with seminal vesicle positive disease and/or capsular penetration and/or positive margins) to radiation vs observation after prostatectomy. A total of 431 subjects with pathologically advanced prostate cancer were randomized. RESULTS: Median followup was 12.2 years. Of the patients 139 had seminal vesicle involvement with or without capsular penetration and/or positive margins. Compared to the 286 patients with seminal vesicle negative disease there was poorer 10-year biochemical failure-free survival (33% for seminal vesicle negative and 22% for seminal vesicle positive, p = 0.04), metastasis-free survival (70% and 56%, respectively, p = 0.005) and overall survival (10-year overall survival 74% and 61%, respectively, p = 0.02) for those with seminal vesicle positive disease. Patients with seminal vesicle positive disease who receivedadjuvant radiation compared to observation realized an improvement in 10-year biochemical failure-free survival from 12% to 36% (p = 0.001), in 10-year overall survival from 51% to 71% (p = 0.08) and in metastasis-free survival from 47% to 66% (p = 0.09), respectively. CONCLUSIONS: Although seminal vesicle involvement is a negative prognostic factor, long-term control is possible especially if patients are given adjuvant radiation therapy. This therapy appears to be effective in patients with seminal vesicle involvement.
RCT Entities:
PURPOSE: From the randomized study Southwest Oncology Group 8794 we evaluated the effect of seminal vesicle involvement on outcomes and whether those patients benefited from post-prostatectomy adjuvant radiation therapy. MATERIALS AND METHODS: Southwest Oncology Group study 8794 randomized high risk patients (with seminal vesicle positive disease and/or capsular penetration and/or positive margins) to radiation vs observation after prostatectomy. A total of 431 subjects with pathologically advanced prostate cancer were randomized. RESULTS: Median followup was 12.2 years. Of the patients 139 had seminal vesicle involvement with or without capsular penetration and/or positive margins. Compared to the 286 patients with seminal vesicle negative disease there was poorer 10-year biochemical failure-free survival (33% for seminal vesicle negative and 22% for seminal vesicle positive, p = 0.04), metastasis-free survival (70% and 56%, respectively, p = 0.005) and overall survival (10-year overall survival 74% and 61%, respectively, p = 0.02) for those with seminal vesicle positive disease. Patients with seminal vesicle positive disease who received adjuvant radiation compared to observation realized an improvement in 10-year biochemical failure-free survival from 12% to 36% (p = 0.001), in 10-year overall survival from 51% to 71% (p = 0.08) and in metastasis-free survival from 47% to 66% (p = 0.09), respectively. CONCLUSIONS: Although seminal vesicle involvement is a negative prognostic factor, long-term control is possible especially if patients are given adjuvant radiation therapy. This therapy appears to be effective in patients with seminal vesicle involvement.
Authors: Carlos Vargas; Larry L Kestin; Dan W Weed; Daniel Krauss; Frank A Vicini; Alvaro A Martinez Journal: Int J Radiat Oncol Biol Phys Date: 2005-03-01 Impact factor: 7.038
Authors: Christopher W Johnson; Aristotelis G Anastasiadis; James M McKiernan; Laurent Salomon; Samuel Eaton; Erik T Goluboff; Carl A Olsson; Mitchell C Benson Journal: Urol Oncol Date: 2004 Mar-Apr Impact factor: 3.498
Authors: Scott E Eggener; Kimberly A Roehl; Norm D Smith; Jo Ann V Antenor; Misop Han; William J Catalona Journal: J Urol Date: 2005-04 Impact factor: 7.450
Authors: Stephen J Freedland; William J Aronson; Joseph C Presti; Christopher L Amling; Martha K Terris; Bruce Trock; Christopher J Kane Journal: Cancer Date: 2004-04-15 Impact factor: 6.860
Authors: Gregory P Swanson; Michael A Hussey; Catherine M Tangen; Joseph Chin; Edward Messing; Edith Canby-Hagino; Jeffrey D Forman; Ian M Thompson; E David Crawford Journal: J Clin Oncol Date: 2007-06-01 Impact factor: 44.544
Authors: Kosj Yamoah; Amy Walker; Elaine Spangler; Charnita M Zeigler-Johnson; Bruce Malkowicz; David I Lee; Adam P Dicker; Timothy R Rebbeck; Priti Lal Journal: Clin Genitourin Cancer Date: 2014-10-25 Impact factor: 2.872
Authors: Mark D Hurwitz; Jonathan Harris; Oliver Sartor; Ying Xiao; Bobby Shayegan; Paul W Sperduto; Kasra R Badiozamani; Colleen A F Lawton; Eric M Horwitz; Jeff M Michalski; Kevin Roof; David C Beyer; Qiang Zhang; Howard M Sandler Journal: Cancer Date: 2017-03-21 Impact factor: 6.860
Authors: Christopher J Keto; William J Aronson; Martha K Terris; Joseph C Presti; Christopher J Kane; Christopher L Amling; Stephen J Freedland Journal: BJU Int Date: 2011-11-17 Impact factor: 5.588
Authors: Shyama U Tetar; Anna M E Bruynzeel; Lisa Verweij; Omar Bohoudi; Berend J Slotman; Tezontl Rosario; Miguel A Palacios; Frank J Lagerwaard Journal: Phys Imaging Radiat Oncol Date: 2022-07-03
Authors: Ashesh B Jani; Eduard Schreibmann; Subir Goyal; Raghuveer Halkar; Bruce Hershatter; Peter J Rossi; Joseph W Shelton; Pretesh R Patel; Karen M Xu; Mark Goodman; Viraj A Master; Shreyas S Joshi; Omer Kucuk; Bradley C Carthon; Mehmet A Bilen; Olayinka A Abiodun-Ojo; Akinyemi A Akintayo; Vishal R Dhere; David M Schuster Journal: Lancet Date: 2021-05-07 Impact factor: 79.321